Skip to main
SGMT
SGMT logo

SGMT Stock Forecast & Price Target

SGMT Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Sagimet Biosciences is a clinical-stage biopharmaceutical company recognized for its innovative portfolio of selective fatty acid synthase (FASN) inhibitors, notably the lead candidate denifanstat, which has shown significant anti-fibrotic effects and favorable lipid profile improvements in patients with nonalcoholic steatohepatitis (NASH). The company's recent advancements include receiving clearance for the IND application of TVB-3567, its second FASN inhibitor, which reinforces the potential for expanded revenue sources through tiered royalty payments from successful acne treatment outcomes. Overall, the positive data from clinical trials focusing on denifanstat's effects on liver health and cardiovascular markers supports a promising outlook for Sagimet Biosciences's stock, further underpinned by anticipated future product developments and market opportunities.

Bears say

Sagimet Biosciences reported a significant net loss of $16.2 million for the fourth quarter of 2024, translating to a loss of $0.50 per share, indicating challenges in financial performance that may deter investor confidence. The company faces multiple fundamental risks, including the potential for disappointing trial data for its lead drug candidate, denifanstat, as well as hurdles related to regulatory approvals and commercialization prospects, which could limit market opportunity. Additionally, operational funding concerns and possible intellectual property challenges further exacerbate the negative outlook for Sagimet’s stock, as these factors raise uncertainties surrounding the company's future prospects and overall viability.

SGMT has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sagimet Biosciences Inc (SGMT) Forecast

Analysts have given SGMT a Buy based on their latest research and market trends.

According to 9 analysts, SGMT has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sagimet Biosciences Inc (SGMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.